Thompson Siegel & Walmsley LLC Invests $1.29 Million in Myomo, Inc. (NYSEAMERICAN:MYO)

Thompson Siegel & Walmsley LLC bought a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $1,288,000. Thompson Siegel & Walmsley LLC owned approximately 0.66% of Myomo as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in MYO. Barclays PLC acquired a new stake in shares of Myomo in the 3rd quarter valued at approximately $36,000. Jane Street Group LLC acquired a new stake in shares of Myomo in the 3rd quarter valued at approximately $65,000. GSA Capital Partners LLP boosted its holdings in shares of Myomo by 60.8% in the 3rd quarter. GSA Capital Partners LLP now owns 103,342 shares of the company's stock valued at $414,000 after buying an additional 39,085 shares during the last quarter. Calamos Advisors LLC acquired a new stake in shares of Myomo in the 4th quarter valued at approximately $189,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Myomo in the 3rd quarter valued at approximately $401,000. 44.99% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Myomo news, insider Harry Kovelman sold 30,000 shares of Myomo stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total value of $165,000.00. Following the transaction, the insider now owns 97,973 shares in the company, valued at $538,851.50. The trade was a 23.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thomas F. Kirk bought 7,400 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the transaction, the director now owns 255,933 shares of the company's stock, valued at approximately $1,279,665. The trade was a 2.98 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.54% of the stock is owned by company insiders.

Remove Ads

Myomo Stock Performance

Shares of MYO traded up $0.17 during midday trading on Wednesday, reaching $5.48. 380,409 shares of the stock were exchanged, compared to its average volume of 496,104. Myomo, Inc. has a twelve month low of $2.51 and a twelve month high of $7.17. The company has a market capitalization of $165.77 million, a P/E ratio of -23.83 and a beta of 1.68.

Analyst Ratings Changes

Several equities research analysts have issued reports on MYO shares. Alliance Global Partners reaffirmed a "buy" rating on shares of Myomo in a report on Tuesday, March 11th. Craig Hallum raised their price target on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. HC Wainwright raised their price target on Myomo from $7.50 to $9.50 and gave the company a "buy" rating in a report on Wednesday, March 12th. Finally, Ascendiant Capital Markets raised their price target on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a report on Monday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $9.75.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.